Long Noncoding RNA Interleukin 6 Antisense RNA 1 Promotes Inflammatory Effects in Lung Macrophages via Exosomes Through the S100A9/TLR4 Pathway in Chronic Obstructive Pulmonary Disease Progression

share:

Brief intro:

  • Author: Erkang Yi, Xiaoyu Wang, Yu Liu, Zihui Wang, Ge Bai, Xinyue Mei, Fan Wu, Chengshu Xie, QiYang Li, Weitao Cao, Huahua Xu, Xinyuan Liu, Jieda Cui, Haiqing Li, Ruiting Sun, Xinru Ran, Wei Hong, Zhishan Deng, Bing Li, Yumin Zhou, Pixin Ran
  • Journal: MedComm (2020)
  • Doi: https://www.doi.org/10.1002/mco2.70204
  • Publication Date: 2025 Jun 6

Products/Services used in the paper

Request Quote

Abstract

This study investigates the role of interleukin 6 antisense RNA 1 (IL6‐AS1), a highly expressed long noncoding RNA (lncRNA), in chronic obstructive pulmonary disease (COPD). An adeno‐associated virus (AAV) was used to induce the expression of IL6‐AS1 in mice, and they were exposed to cigarette smoke to establish a COPD model. IL6‐AS1‐overexpressing mice exposed to cigarette smoke demonstrated exacerbated COPD‐like pathologies. Integrated with single‐cell RNA sequencing analysis of COPD patients and pulmonary fibroblast–macrophage coculture system, our findings indicate that the upregulation of IL6‐AS1 in fibroblasts enhances the interaction between the S100A9 protein and the AGER and TLR4 receptors on lung macrophages, thereby exacerbating pulmonary inflammation. The molecular mechanism likely involves exosome‐mediated secretion, with IL6‐AS1 binding to S100A9 protein. These findings suggest that IL6‐AS1 may facilitate crosstalk between fibroblasts and macrophages, contributing to increased pulmonary inflammation, an effect that can be blocked by paquinimod. Mendelian randomization analysis further suggests a potential shared causal variant between IL6‐AS1 and COPD risk. Taken together, this investigation provides valuable insights into the function of IL6‐AS1 and its potential implications for the pathogenesis and therapeutic strategies in COPD.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download

Login

Don't have an account? Please register
Account*
Password*
Code*
Refresh
Forgot password?
Logging in indicates that you have read and accepted the Registration Agreement and User Agreement
Log in with other accounts

New User Registration

Already have an account?
First Name*
Middle Name
Last Name*
Organization*
Organization Type*
Country/State*
Email Address*
Code*
Set Password*
Confirm password*
Refferal Code*

Reset Password

Return to
Email*
Code*
New password*
Confirm password*

Google Account Binding

Organization*
Organization Type*
Country/State*